Phase I clinical and pharmacokinetic study ofN4-behenoyl-1-β-d-arabinofuranosylcytosine
✍ Scribed by Kiyoji Kimura; Ryuzo Ohno; Ichita Amaki; Kenichi Hattori; Yutaka Hirota; Akira Hoshino; Michito Ichimaru; Munemoto Ito; Ikuo Kimura; Tadashi Maekawa; Toru Masaoka; Toru Nakamura; Makoto Ogawa; Masao Oguro; Kazuo Ohta; Shigeyuki Osamura; Masanori Shimoyama; Fumimaro Takaku; Yoshiro Uzuka; Kazumasa Yamada
- Book ID
- 112944133
- Publisher
- Springer US
- Year
- 1986
- Tongue
- English
- Weight
- 633 KB
- Volume
- 3
- Category
- Article
- ISSN
- 1357-0560
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract The antiviral activities of antileukemic drugs 1‐β‐D‐arabinofuranosylcytosine (Cytarabine; Ara‐C), 2,2′‐anhydro‐1‐β‐D‐arabinofuranosylcytosine (Ancitabine; Cyclo‐C), and N^4^‐behenoyl‐1‐β‐D‐arabinofuranosylcytosine (Enocitabine; BH‐AC) were evaluated in vitro against human cytomegalovir
The effects of N4-behenoyl-l-~-~-arabinofuranosylcytosine (BH-AC) on the cell cycle of murine leukemic cells (L 1210 cells) were compared with those of 1-8-D-arabinofuranosylcytosine (ara-C), known to be effective for acute leukemia. In a cytokinetic study, a combination of Feulgen microcytofluorome